Titan Pharmaceuticals Inc. (NASDAQ:TTNP) Q1 2020 Earnings Conference Call - Final Transcript
May 15, 2020 • 12:00 pm ET
Good day, everybody, and thank you for holding. Welcome to the Titan Pharmaceuticals First Quarter 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session following today's remarks. Please be advised that this call is being recorded at the Company's request and will be archived on the Company's website, starting later today.
At this time, I would like to hand the conference over to Sunil Bhonsle, President and CEO of Titan Pharmaceuticals. Please go ahead.
Thank you, Eric, and thank you all for joining us. Welcome to the Titan Pharmaceuticals' call to review financial and operational results for the first quarter ended March 31, 2020, and provide an update on our business.
It's been only six weeks since the last call at the end of March, but with the changing environment we have encountered, these have been very busy indeed. Before we begin, I wanted to inform you that we have filed our quarterly report on Form 10-Q with the SEC, and the press release issued earlier today provides a summary of the results, and can be found on our website at titanpharm.com.
Joining me on the call today from Titan are Dr. Marc Rubin, our Executive Chairman; Dr. Kate DeVarney, Executive Vice President and Chief Scientific Officer; and Brian Crowley, Vice President of Finance.
Before we get into the details of the financial results and provide an update on the Company, Jennifer Kiernan will review the required cautions regarding forward-looking statements. Jennifer?
Thank you, Sunil. I want to remind everyone that certain matters that will be discussed today, other than historical information, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product commercialization and development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.
Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the commercialization of Probuphine; the regulatory approval process; Titan's ability to access capital, the development, testing, production and marketing of our drug candidates; patent and intellectual property matters; and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. And now, back to you, Sunil.
Thank you, Jennifer.
We will start the call with an overview from our Executive Chairman, Dr. Marc Rubin. And, as you know, Dane Hallberg is no longer at Titan. So, I will provide an update of the commercial activity, followed by medical affairs, regulatory and product development updates from